SAEs · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
It is very uncertain whether erythromycin changes all‐cause mortality compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
NSAEs · people with acute UGIH
It is very uncertain whether erythromycin changes NSAEs compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin changes rebleeding compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review
Relapse · Participants with Crohn's disease in remission
It is very uncertain whether elemental formula supplements changes relapse compared with polymeric formula supplements (very low certainty).
1 finding from 1 review
Change in weight (kg) · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in height · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).
1 finding from 1 review
Death Analysis 1.1 · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in death from all causes ‐ modified ITT analysis compared with control (moderate certainty).
1 finding from 1 review
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis · healthy asymptomatic H. pylori‐infected individuals
H. pylori eradication therapy showed no clear difference in incidence of oesophageal squamous cell carcinoma ‐ modified ITT… compared with control (moderate certainty).
1 finding from 1 review
Adverse events · healthy asymptomatic H. pylori‐infected individuals
1 finding from 1 review
Intervention not reported
Incidence of AAD · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD: Probiotic dose (≥5 billion CFUs of probiotics/day) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Duration of diarrhea (days) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Intervention not reported
Microbiome characteristics · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review